Hot Keywords
Ageing Neurodegenerative Diseases Neurodegeneration AD

Topic: Advances in Parkinson and Atypical Parkinson's Diseases

A special issue of Ageing and Neurodegenerative Diseases

ISSN 2769-5301 (Online)

Submission deadline: 26 Oct 2023

Guest Editor(s)

  • Prof. David Finkelstein
    Parkinsons Disease Lab, The Florey Institute, Victoria, Australia.

    Website | E-mail

  • Prof. Qing Wang

    Department of Neurology in Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

    Website | E-mail

Special Issue Introduction

Unfortunately, the number of people with Parkinson's (PD) and Atypical Parkinsons Disease is predicted to double in the next decade, probably due to increased lifespan and environmental conditions. However, the field has been rapidly advancing our understanding of the conditions. There appear to be two types of PD: Roughly 50% have a "Brain First" condition that shows a particular REM sleep behavior disorder (RBD). These exhibit prodromal symptoms up to 10 years before clinical PD. The other 50% are "Gut-First Parkinson's", with symptoms occurring first in the periphery (gut, heart) and then the brain.

In conjunction with MRI, positron emission tomography (PET) imaging studies can recognize the early disease and, recently, a ligand to alpha-synuclein that can identify people with Multiple system atrophy (MSA). However, this only partially addresses the urgent need for biomarkers to identify the types of Parkinson's and Atypical Parkinsons Diseases that can monitor disease progression. New therapeutic development will depend on these biomarkers.

While much of the focus is on early diagnosis and treatment, there are important advances in therapies that improve the quality of life of people living with Parkinson's and Atypical Parkinsons Diseases. Restorative cell replacement therapies have also made significant advances in using cells that meet Good manufacturing practice (GMP) standards.

This special issue will attempt to bring together recent advances in the field.


Alpha-synuclein, diagnosis, disease progression, cell replacement therapies, MRI imaging, PET imaging, prodromal Parkinsons, environmental risk factors

Submission Deadline

26 Oct 2023

Submission Information

For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 26 Oct 2023
Contacts: Leila Wang, Assistant Editor,

Published Articles

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties